{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.3.', 'Treatment of Overdose', 'For this study, any dose of study treatment 4 tablets in a day will be considered an', 'overdose.', 'GSK does not recommend specific treatment for an overdose.', 'In the event of an overdose, the investigator/treating physician should:', '1. Contact the Medical Monitor immediately.', '2. Closely monitor the participant for AE/SAE and laboratory abnormalities until study', 'treatment can no longer be detected systemically (at least 3 days).', '3. Obtain a plasma sample for PK analysis as soon as possible from the date of the last', 'dose of study treatment if requested by the Medical Monitor (determined on a case-', 'by-case basis).', '4. Document the quantity of the excess dose as well as the duration of the overdosing in', 'the CRF.', 'Decisions regarding dose interruptions or modifications will be made by the investigator', 'in consultation with the Medical Monitor based on the clinical evaluation of the', 'participant.', '9.4.', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the SoA.', '9.4.1.', 'Physical Examinations', 'A complete physical examination will include, at a minimum, assessments of the', 'skin, cardiovascular, respiratory, gastrointestinal and neurological systems.', 'Height and weight will also be measured and recorded.', 'A brief physical examination will include, at a minimum, assessments of the', 'skin, lungs, cardiovascular system, and abdomen (liver and spleen).', 'Investigators should pay special attention to clinical signs related to previous', 'serious illnesses.', '9.4.2.', 'Vital Signs', 'Vital signs will be measured in a semi-supine position after 5 minutes rest and will', 'include systolic and diastolic blood pressure, pulse, and respiratory rate. Three readings', 'of blood pressure and pulse will be taken. The first reading should be rejected. The', 'second and third readings should be averaged to give the measurement to be recorded in', 'the CRF. A single measurement of respiratory rate is adequate.', '43']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.4.3.', 'Electrocardiograms', 'For participant screening and pre-dose on Day 1, triplicate ECG measurements should be', 'collected. For all subsequent ECG assessments, single measurements are to be collected.', '12-lead ECG will be obtained as outlined in the SoA using an ECG machine that', 'automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.', 'Refer to Section 8.1.2 for QTc withdrawal criteria and additional QTc readings that may', 'be necessary.', 'At each time point at which triplicate ECG are required, 3 individual ECG tracings', 'should be obtained as closely as possible in succession, but no more than 2 minutes apart.', 'The full set of triplicates should be completed in less than 10 minutes.', '9.4.4.', 'Clinical Safety Laboratory Assessments', 'Refer to Section 12.2 (Appendix 2) for the list of clinical laboratory tests to be performed', 'and to the SoA for the timing and frequency.', 'The investigator must review the laboratory report, document this review, and record', 'any clinically relevant changes occurring during the study in the AE section of the', 'CRF. The laboratory reports must be filed with the source documents. Clinically', 'significant abnormal laboratory findings are those which are not associated with the', 'underlying disease, unless judged by the investigator to be more severe than', \"expected for the participant's condition.\", 'All laboratory tests with values considered abnormal and clinically significant during', 'participation in the study or within 3 days after the last dose of study treatment', 'should be repeated until the values return to normal or baseline or are no longer', 'considered significantly abnormal by the investigator or medical monitor.', 'If such values do not return to normal/baseline within a period of time judged', 'reasonable by the investigator, the etiology should be identified and the sponsor', 'notified.', 'All protocol-required laboratory assessments, as defined in Section 12.2, must be', 'conducted in accordance with the laboratory manual and the SoA (Table 1).', 'If laboratory values from non-protocol specified laboratory assessments performed at', \"the institution's local laboratory require a change in participant management or are\", 'considered clinically significant by the investigator (e.g., SAE or AE), then the', 'results must be recorded in the CRF.', '9.4.5.', 'Pneumonia', 'All suspected pneumonias will require confirmation as defined by the presence or new', 'infiltrate(s) on chest x-ray AND at least 2 of the following signs and symptoms:', 'Increased cough', 'Increased sputum purulence (colour) or production', 'Auscultatory findings of adventitious sounds (e.g. egophony, bronchial breath', 'sounds, rales, etc.)', '44']\n\n###\n\n", "completion": "END"}